US-based Cardiome Pharma has named Lebanons Algorithm as the exclusive seller and distributor for its intravenous investigational drug BRINAVESS, in certain parts of North Africa and the Middle East
Cardiome Pharma did not disclose the financial terms of the agreement with Algorithm.
In a company statement, Cardiome Pharma said the commercial sale and distributors agreement with the pharmaceutical manufacturer, which is effective from November 2013, would run for a period of five years.
The drug, which is used to investigate heart disorders, would be sold in Algeria, Bahrain, Egypt, Iran, Jordan, Saudi Arabia, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Tunisia and the UAE.
Cardiome Pharma chief commercial officer Karim Lalji said, “We are pleased to have entered into this agreement with Algorithm. We look forward to continuing the commercialisation of BRINAVESS in approved markets.”
Algorithm human health lead officer Nabil Ghorayeb added, “Our company has a long and successful history in the cardiovascular market and BRINAVESS is an excellent addition to our product portfolio that would offer customers a treatment option for the early onset of atrial fibrillation.”
